A Phase 2 interventional study of Denosumab and IV Bisphosphonates in Breast Cancer, Metastases and Bone Metastases in Subjects With Advanced Breast Cancer, sponsored by Amgen. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-01-28.
Sponsored by Amgen · Phase 2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing denosumab in Breast Neoplasms — none open to participants now, 3 under way, 2 of them phase 3. Denosumab · Breast Neoplasms.
Among the 24 studies testing denosumab in Breast Neoplasms, this one is the 7th largest by enrollment, is one of 2 that started in 2004, is one of 9 in phase 2, and was the 2nd registered.
14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →None of the 24 studies testing denosumab in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 255 is above the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.
Median enrollment 53 across the 24 interventional studies. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 24 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
30 studies in Breast Neoplasms by Amgen: none open now, 1 under way, 1 of them phase 3. Of 29 finished, 16 (55%) have results posted.
Among the 30 studies in Breast Neoplasms by Amgen, this one is the 10th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2004, is one of 12 in phase 2, and was the 4th registered.
Amgen’s Breast Neoplasms studies by the year they started, since 2002.
1 of the studies testing denosumab in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04711109Phase 3Alliance for Clinical Trials in OncologyStudying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies testing denosumab in Breast Neoplasms, from their registry updates:
Among Amgen’s 30 in Breast Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to evaluate various doses and schedules for denosumab administration and characterize the safety profile in this indication.
Inclusion Criteria: - or cytologically confirmed breast adenocarcinoma
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Denosumab 60 mg by subcutaneous injection once every 12 weeks (Q12W) for 25 weeks.
Biological: Denosumab
Denosumab 120 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.
Biological: Denosumab
Denosumab 180 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.
Biological: Denosumab
Open label bisphosphonate every 4 weeks (Q4W) by intravenous infusion for 25 weeks.
Drug: IV Bisphosphonates
Denosumab 180 mg by subcutaneous injection once every 12 weeks (Q12W) for 25 weeks.
Biological: Denosumab
Denosumab 30 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.
Biological: Denosumab
Denosumab administered by subcutaneous injection
Also known as: AMG 162
Commercially available intravenous (IV) bisphosphonates administered per package insert, included pamidronate, ibandronic acid, and zoledronic acid
Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr)
Percent change from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr) calculated using ((Week 13 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and Week 13
Percent Change From Baseline to Week 25 in Urinary N-telopeptide (uNTx)
Percent change from Baseline to Week 25 in Urinary N-telopeptide (uNTx) calculated using ((Week 25 value - Baseline value) / Baseline value) x 100.
Time frame: Baseline and Week 25
Number of Participants Achieving 65% or More Reduction in Urinary N-telopeptide (uNTx) From Baseline at Week 13
The number of participants achieving a 65% reduction or more in uNTx from Baseline at Week 13. Calculation used is ((Week 13 value - Baseline value) / Baseline value ) x 100 and participants were considered having a 65% reduction or more if their value was ≤ -65%.
Time frame: Baseline and Week 13
Number of Participants Achieving 65% or More Reduction in uNTX From Baseline at Week 25
The number of participants achieving a 65% reduction or more in uNTX from Baseline at Week 25. Calculation used is ((Week 25 value - Baseline value) / Baseline value) x 100 and participants were considered having a 65% reduction or more if their value was ≤ -65%.
Time frame: Baseline and Week 25
Time to 65% or More Reduction in Urinary N-telopeptide (uNTX) From Baseline
Kaplan-Meier estimate of the median time from enrollment to the first occurrence of a reduction of uNTx of ≥ 65% compared to Baseline. For participants whose uNTx did not fall below 65% of the Baseline value, the time was censored at time of last evaluation of uNTx.
Time frame: Baseline to Week 57
Percent Change From Baseline to Week 13 in Serum C-Telopeptide (CTX)
Percent change from Baseline to Week 13 in type I serum C-telopeptide (CTX) calculated using ((Week 13 value - Baseline value) / Baseline value) x 100.
Time frame: Baseline and week 13
Percent Change From Baseline to Week 25 in Serum C-telopeptide (CTX)
Percent change from Baseline to Week 25 in type I serum C-telopeptide calculated using ((Week 25 value - Baseline value) / Baseline value) x 100.
Time frame: Baseline and Week 25
Percent Change From Baseline to Week 13 in Procollagen I N-terminal Peptide (P1NP)
Percent change from Baseline to Week 13 in procollagen 1 N-terminal peptide calculated using ((Week 13 value - Baseline value) / Baseline value) x 100.
Time frame: Baseline and Week 13
Percent Change From Baseline to Week 25 in P1NP
Percent change from Baseline to Week 25 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Week 25 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and Week 25
Percent Change From Baseline to Week 13 in Tartrate-resistant Acid Phosphatase 5b (TRAP5b)
Percent change from Baseline to Week 13 in tartrate-resistant acid phosphatase 5b calculated using ((Week 13 value - Baseline value) / Baseline value) x 100.
Time frame: Baseline and Week 13
Percent Change From Baseline to Week 25 in Tartrate-resistant Acid Phosphatase 5b (TRAP5b)
Percent change from Baseline to Week 25 in TRAP5b calculated using ((Week 25 value - Baseline value) / Baseline value) x 100.
Time frame: Baseline and Week 25
Percent Change From Baseline to Week 13 in Bone Specific Alkaline Phosphatase (BSAP)
Percent change from Baseline to Week 13 in bone specific alkaline phosphatase (BSAP) calculated using ((Week 13 value - Baseline value) / Baseline value) x 100.
Time frame: Baseline and Week 13
Percent Change From Baseline to Week 25 in Bone Specific Alkaline Phosphatase (BSAP)
Percent change from Baseline to Week 25 in BSAP calculated using ((Week 25 value - Baseline value) / Baseline value) x 100.
Time frame: Baseline and Week 25
Percent Change From Baseline to Week 13 in Osteocalcin
Percent change from Baseline to Week 13 in osteocalcin calculated using ((Week 13 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and Week 13
Percent Change From Baseline to Week 25 in Osteocalcin
Percent change from Baseline to Week 25 in osteocalcin calculated using ((Week 25 value - Baseline value) / Baseline value) x 100.
Time frame: Baseline and Week 25
Time to First Skeletal Related Event
Skeletal Related Event (SRE) defined as ≥ 1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes).
Time frame: Day 1 to Week 25
Number of Participants With Skeletal Related Events
Skeletal Related Events (SRE) are defined as ≥ 1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes).
Time frame: From Day 1 to Week 25
Number of Participants With Hypercalcemia
Occurrence of grade 3 or 4 hypercalcemia according to the Common Terminology Criteria for Adverse Events (CTCAE) v3. A summary of hypercalcemia events is reported under adverse events.
Time frame: Day 1 to Week 57
Participants were enrolled from 8 September 2004 through 9 May 2005
| Milestone | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W |
|---|---|---|---|---|---|---|
| Started | 43 | 42 | 42 | 43 | 42 | 43 |
| Received study medication | 43 | 42 | 41 | 43 | 42 | 43 |
| Completed | 29 | 31 | 30 | 29 | 27 | 32 |
| Not completed | 14 | 11 | 12 | 14 | 15 | 11 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 3 | 0 |
| Withdrew: Withdrawal by subject | 4 | 5 | 0 | 1 | 3 | 1 |
| Withdrew: Death | 6 | 4 | 5 | 8 | 5 | 6 |
| Withdrew: Disease progression | 2 | 0 | 0 | 1 | 1 | 2 |
| Withdrew: Ineligibility determined | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 3 | 3 | 2 | 1 |
| Withdrew: Noncompliance | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 0 | 1 |
Percent change from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr) calculated using ((Week 13 value - Baseline value) / Baseline value ) x 100.
| Percent change | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W |
|---|---|---|---|---|---|---|
| Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr) | -10.19 ± 208.84 | -52.87 ± 95.14 | -54.21 ± 61.34 | -57.36 ± 41.46 | -51.73 ± 60.85 | -18.46 ± 125.86 |
Percent change from Baseline to Week 25 in Urinary N-telopeptide (uNTx) calculated using ((Week 25 value - Baseline value) / Baseline value) x 100.
| Percent change | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W |
|---|---|---|---|---|---|---|
| Percent Change From Baseline to Week 25 in Urinary N-telopeptide (uNTx) | -39.52 ± 74.16 | -53.46 ± 100.77 | -43.16 ± 101.08 | -59.41 ± 43.31 | -41.79 ± 72.61 | -39.96 ± 65.85 |
The number of participants achieving a 65% reduction or more in uNTx from Baseline at Week 13. Calculation used is ((Week 13 value - Baseline value) / Baseline value ) x 100 and participants were considered having a 65% reduction or more if their value was ≤ -65%.
| Participants | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W |
|---|---|---|---|---|---|---|
| Number of Participants Achieving 65% or More Reduction in Urinary N-telopeptide (uNTx) From Baseline at Week 13 | 25 | 24 | 26 | 24 | 20 | 21 |
The number of participants achieving a 65% reduction or more in uNTX from Baseline at Week 25. Calculation used is ((Week 25 value - Baseline value) / Baseline value) x 100 and participants were considered having a 65% reduction or more if their value was ≤ -65%.
| Participants | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W |
|---|---|---|---|---|---|---|
| Number of Participants Achieving 65% or More Reduction in uNTX From Baseline at Week 25 | 19 | 25 | 23 | 25 | 21 | 15 |
Kaplan-Meier estimate of the median time from enrollment to the first occurrence of a reduction of uNTx of ≥ 65% compared to Baseline. For participants whose uNTx did not fall below 65% of the Baseline value, the time was censored at time of last evaluation of uNTx.
| Days | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W |
|---|---|---|---|---|---|---|
| Time to 65% or More Reduction in Urinary N-telopeptide (uNTX) From Baseline | 10 (8 to 86) | 13 (8 to 57) | 11 (9 to 43) | 10 (8 to 42) | 9 (8 to 29) | 30 (9 to 141) |
Percent change from Baseline to Week 13 in type I serum C-telopeptide (CTX) calculated using ((Week 13 value - Baseline value) / Baseline value) x 100.
| Percent change | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W |
|---|---|---|---|---|---|---|
| Percent Change From Baseline to Week 13 in Serum C-Telopeptide (CTX) | -66.92 ± 44.05 | -80.76 ± 12.66 | -78.45 ± 28.89 | -81.79 ± 13.29 | -70.50 ± 41.76 | -78.13 ± 16.66 |
Percent change from Baseline to Week 25 in type I serum C-telopeptide calculated using ((Week 25 value - Baseline value) / Baseline value) x 100.
| Percent change | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W |
|---|---|---|---|---|---|---|
| Percent Change From Baseline to Week 25 in Serum C-telopeptide (CTX) | -73.09 ± 22.42 | -82.70 ± 11.92 | -74.48 ± 30.26 | -80.07 ± 22.26 | -70.64 ± 36.94 | -78.31 ± 14.00 |
Percent change from Baseline to Week 13 in procollagen 1 N-terminal peptide calculated using ((Week 13 value - Baseline value) / Baseline value) x 100.
| Percent change | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W |
|---|---|---|---|---|---|---|
| Percent Change From Baseline to Week 13 in Procollagen I N-terminal Peptide (P1NP) | -50.75 ± 29.47 | -52.35 ± 36.90 | -48.23 ± 36.83 | -50.47 ± 54.67 | -43.94 ± 44.53 | -59.42 ± 18.60 |
Percent change from Baseline to Week 25 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Week 25 value - Baseline value) / Baseline value ) x 100.
| Percent change | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W |
|---|---|---|---|---|---|---|
| Percent Change From Baseline to Week 25 in P1NP | -50.48 ± 41.22 | -53.48 ± 54.79 | -55.90 ± 30.66 | -57.88 ± 51.97 | -51.18 ± 40.41 | -51.37 ± 47.53 |
Percent change from Baseline to Week 13 in tartrate-resistant acid phosphatase 5b calculated using ((Week 13 value - Baseline value) / Baseline value) x 100.
| Percent change | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W |
|---|---|---|---|---|---|---|
| Percent Change From Baseline to Week 13 in Tartrate-resistant Acid Phosphatase 5b (TRAP5b) | -37.45 ± 19.87 | -56.07 ± 17.80 | -58.24 ± 15.07 | -53.12 ± 50.00 | -55.85 ± 27.22 | -55.91 ± 17.61 |
Percent change from Baseline to Week 25 in TRAP5b calculated using ((Week 25 value - Baseline value) / Baseline value) x 100.
| Percent change | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W |
|---|---|---|---|---|---|---|
| Percent Change From Baseline to Week 25 in Tartrate-resistant Acid Phosphatase 5b (TRAP5b) | -38.59 ± 26.06 | -58.58 ± 18.93 | -52.39 ± 25.30 | -51.15 ± 44.49 | -56.25 ± 32.30 | -53.13 ± 22.23 |
Percent change from Baseline to Week 13 in bone specific alkaline phosphatase (BSAP) calculated using ((Week 13 value - Baseline value) / Baseline value) x 100.
| Percent change | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W |
|---|---|---|---|---|---|---|
| Percent Change From Baseline to Week 13 in Bone Specific Alkaline Phosphatase (BSAP) | -40.01 ± 24.42 | 26.37 ± 406.79 | -40.23 ± 27.34 | -38.42 ± 25.44 | -37.11 ± 31.33 | -35.94 ± 25.49 |
Percent change from Baseline to Week 25 in BSAP calculated using ((Week 25 value - Baseline value) / Baseline value) x 100.
| Percent change | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W |
|---|---|---|---|---|---|---|
| Percent Change From Baseline to Week 25 in Bone Specific Alkaline Phosphatase (BSAP) | -46.56 ± 26.02 | 15.88 ± 347.47 | -49.01 ± 21.24 | -52.60 ± 16.23 | -46.72 ± 23.25 | -48.24 ± 27.61 |
Percent change from Baseline to Week 13 in osteocalcin calculated using ((Week 13 value - Baseline value) / Baseline value ) x 100.
| Percent change | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W |
|---|---|---|---|---|---|---|
| Percent Change From Baseline to Week 13 in Osteocalcin | 6.82 ± 49.78 | -19.35 ± 38.71 | -2.39 ± 47.96 | -6.23 ± 40.82 | -23.78 ± 35.46 | -5.96 ± 41.92 |
Percent change from Baseline to Week 25 in osteocalcin calculated using ((Week 25 value - Baseline value) / Baseline value) x 100.
| Percent change | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W |
|---|---|---|---|---|---|---|
| Percent Change From Baseline to Week 25 in Osteocalcin | -4.74 ± 86.98 | -30.78 ± 34.94 | -22.80 ± 46.36 | -26.95 ± 41.49 | -23.93 ± 43.99 | -22.69 ± 36.79 |
Skeletal Related Event (SRE) defined as ≥ 1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes).
| Days | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W |
|---|---|---|---|---|---|---|
| Time to First Skeletal Related Event | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Skeletal Related Events (SRE) are defined as ≥ 1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes).
| Participants | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W |
|---|---|---|---|---|---|---|
| Number of Participants With Skeletal Related Events | 7 | 4 | 8 | 6 | 4 | 4 |
Occurrence of grade 3 or 4 hypercalcemia according to the Common Terminology Criteria for Adverse Events (CTCAE) v3. A summary of hypercalcemia events is reported under adverse events.
| Participants | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W |
|---|---|---|---|---|---|---|
| Number of Participants With Hypercalcemia | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over 25 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bisphosphonate IV Q4W | — | 15/43 (34.9%) | 36/43 (83.7%) |
| Denosumab 30 mg Q4W | — | 11/42 (26.2%) | 33/42 (78.6%) |
| Denosumab 120 mg Q4W | — | 19/41 (46.3%) | 37/41 (90.2%) |
| Denosumab 180 mg Q4W | — | 16/43 (37.2%) | 36/43 (83.7%) |
| Denosumab 60 mg Q12W | — | 14/42 (33.3%) | 37/42 (88.1%) |
| Denosumab 180 mg Q12W | — | 15/43 (34.9%) | 35/43 (81.4%) |
| Event | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W |
|---|---|---|---|---|---|---|
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/43 | 0/42 | 3/41 | 0/43 | 4/42 | 0/43 |
| General physical health deteriorationGeneral disorders | 0/43 | 0/42 | 1/41 | 4/43 | 0/42 | 1/43 |
| AnaemiaBlood and lymphatic system disorders | 0/43 | 1/42 | 3/41 | 0/43 | 2/42 | 1/43 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/43 | 0/42 | 2/41 | 0/43 | 3/42 | 0/43 |
| VomitingGastrointestinal disorders | 0/43 | 0/42 | 2/41 | 1/43 | 0/42 | 1/43 |
| PyrexiaGeneral disorders | 1/43 | 0/42 | 2/41 | 1/43 | 0/42 | 1/43 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/43 | 0/42 | 2/41 | 1/43 | 0/42 | 0/43 |
| NauseaGastrointestinal disorders | 0/43 | 0/42 | 1/41 | 0/43 | 0/42 | 2/43 |
| Urinary tract infectionInfections and infestations | 2/43 | 0/42 | 0/41 | 0/43 | 0/42 | 0/43 |
| CachexiaMetabolism and nutrition disorders | 0/43 | 1/42 | 1/41 | 2/43 | 1/42 | 0/43 |
| Event | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W |
|---|---|---|---|---|---|---|
| AstheniaGeneral disorders | 12/43 | 9/42 | 9/41 | 4/43 | 6/42 | 5/43 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 12/43 | 3/42 | 4/41 | 9/43 | 5/42 | 3/43 |
| VomitingGastrointestinal disorders | 8/43 | 11/42 | 7/41 | 5/43 | 7/42 | 4/43 |
| NauseaGastrointestinal disorders | 10/43 | 10/42 | 9/41 | 11/43 | 7/42 | 9/43 |
| DiarrhoeaGastrointestinal disorders | 7/43 | 9/42 | 9/41 | 6/43 | 4/42 | 6/43 |
| Back painMusculoskeletal and connective tissue disorders | 4/43 | 7/42 | 9/41 | 5/43 | 4/42 | 5/43 |
| MyalgiaMusculoskeletal and connective tissue disorders | 9/43 | 3/42 | 1/41 | 1/43 | 1/42 | 2/43 |
| HeadacheNervous system disorders | 7/43 | 4/42 | 6/41 | 6/43 | 8/42 | 4/43 |
| PyrexiaGeneral disorders | 8/43 | 2/42 | 4/41 | 3/43 | 3/42 | 3/43 |
| Bone painMusculoskeletal and connective tissue disorders | 8/43 | 2/42 | 7/41 | 6/43 | 5/42 | 4/43 |
| Age, Continuous(Years) | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Total |
|---|---|---|---|---|---|---|---|
| Mean | 52.0 ± 10.7 | 56.5 ± 10.8 | 59.2 ± 12.3 | 58.2 ± 9.1 | 57.4 ± 11.0 | 57.6 ± 13.9 | 57.8 ± 11.4 |
| Sex: Female, Male(Participants) | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Total |
|---|---|---|---|---|---|---|---|
| Female | 43 | 42 | 42 | 43 | 42 | 43 | 255 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Total |
|---|---|---|---|---|---|---|---|
| White or Caucasian | 25 | 28 | 29 | 34 | 30 | 33 | 179 |
| Hispanic or Latino | 16 | 13 | 13 | 9 | 10 | 10 | 71 |
| Asian | 1 | 0 | 0 | 0 | 1 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Other | 1 | 0 | 0 | 0 | 1 | 0 | 2 |
| uNTx/Cr(nmol/mmol) | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Total |
|---|---|---|---|---|---|---|---|
| Mean | 83.16 ± 94.37 | 66.44 ± 61.17 | 89.41 ± 98.58 | 75.92 ± 91.03 | 102.06 ± 129.12 | 98.22 ± 168.42 | 85.78 ± 111.94 |
| Serum CTx(ng/mL) | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Total |
|---|---|---|---|---|---|---|---|
| Mean | 0.592 ± 0.284 | 0.632 ± 0.430 | 0.720 ± 0.559 | 0.647 ± 0.703 | 0.714 ± 0.564 | 0.846 ± 0.892 | 0.692 ± 0.605 |
| TRAP 5b(U/L) | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Total |
|---|---|---|---|---|---|---|---|
| Mean | 6.907 ± 3.280 | 6.879 ± 2.878 | 7.116 ± 3.493 | 7.628 ± 6.830 | 6.765 ± 4.340 | 7.009 ± 4.217 | 7.057 ± 4.358 |
| BSAP(U/L) | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Total |
|---|---|---|---|---|---|---|---|
| Mean | 54.84 ± 51.69 | 44.33 ± 26.06 | 45.62 ± 26.02 | 62.39 ± 109.18 | 47.89 ± 30.46 | 48.82 ± 35.13 | 50.75 ± 55.04 |
| P1NP(µg/L) | Bisphosphonate IV Q4W | Denosumab 30 mg Q4W | Denosumab 60 mg Q12W | Denosumab 180 mg Q12W | Denosumab 120 mg Q4W | Denosumab 180 mg Q4W | Total |
|---|---|---|---|---|---|---|---|
| Mean | 111.01 ± 97.21 | 98.54 ± 72.69 | 114.29 ± 113.51 | 193.03 ± 641.13 | 98.47 ± 83.46 | 139.01 ± 188.02 | 126.20 ± 284.81 |
1 further baseline measures are reported on the registry.
No study locations are listed for this record.
The record gives a start of Sep 2004, a primary completion of Nov 2005 and a completion of Oct 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 5 years 2 months after primary completion. A results delay was requested in Nov 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab